The relationship of HCV RNA levels to HCV genotypes as well as to responses to pegylated interferon and ribavirin therapy in patients with chronic hepatitis C
ZHOU Youqian,YIN Fengming,FENG Jinghua
Department of Infectious Diseases,the 169th Hospital,Hengyang 421002,Hunan Province
ZHOU Youqian,YIN Fengming,FENG Jinghua. The relationship of HCV RNA levels to HCV genotypes as well as to responses to pegylated interferon and ribavirin therapy in patients with chronic hepatitis C[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2011, 14(5): 340-342.
[1] NGUYEN-KHAC E,CAPRON D,ASTELAIN S,et al. Personalized therapy for chronic viral hepatitis C in the naive patient:How can we optimize treatment duration as a function of viral genotype[J]. Eur J Intern Med,2007,18(7):510-515. [2] CHAKRAVARTI A,DOGRA G,VERMA V,et al. Distribution pattern of HCV genotypes & its association with viral load[J].Indian J Med Res,2011,133(3):326-331. [3] FERNáNDEZ I,CASTELLANO G,DOMINGO MJ,et al.Influence of viral genotype and level of viremia on the severity of liver injury and the response to interferon therapy in Spanish patients with chronic C infection[J]. Scand J Gastroenterol,1997,32(1):70-76. [4] Kü?K?ZTAS MF,OZGüNES N,YAZICI S. Investigation of the relationship between hepatitis c virus(HCV)genotypes with HCV-RNA and alanine aminotransferase levels in chronic hepatitis C patients[J]. Mikrobiyol Bul,2010,44(1):111-115. [5] YU ML,CHUANG WL. Treatment of chronic hepatitis C in Asia:when East meets West[J]. J Gastroenterol Hepatol,2009,24(3):336-345. [6] 张帆,王小红,王宇明,等. 重庆地区HCV基因亚型的分布状态[J]. 第四军医大学学报,2005,26(14):1253-1256. [7] JENS B,PHILIP M,RAYMOND T,et al. Challenge pools of hepatitis C virus genotypes 1-6 prototype strains:Replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models[J]. J Infect Dis,2010,201(9):1381-1389. [8] ELKADY A,TANAKA Y,KURBANOV F,et al. Performance of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA:evaluation on HCV genotypes 1-4[J]. J Med Virol,2010,82(11):1878-1888. [9] SIMMONDS P,BUKH J,COMBET C,et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes[J]. Hepatology,2005,42(4):962-973. [10] CANTALOUBE JF,LAPERCHE S,GALLIAN P,et al. Analysis of the 5' noncoding region versus the NS5b region in genotyping hepatitis C virus isolates from blood donors in France[J]. J Clin Microbiol,2006,44(6):2051-2056. [11] SCHINKEL J,KROES AC,WAGTMANS MJ,et al. Monitoring response during a randomised controlled trial of escalating interferon dose for chronic hepatitis C infection:predictive value of quantitative and qualitative HCV RNA assays[J]. J Clin Virol,2001,22(1):61-71. [12] TAKENOKUCHI M,YASUDA C,NAKAMACHI Y,et al. Comparative evaluation of serum HCV RNA by Roche Monitor Assay. Versions 1.0 and 2.0;as a predictive marker of subsequent response to IFN therapy[J]. Rinsho Byori,2002,50(4):392-397. [13] LEE SD,YU ML,CHENG PN,et al. Comparison of a 6-month course peginterferon a-2b plus ribavirin and interferon a-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan[J]. J Viral Hepatitis,2005,12,283-291. [14] DAVID LT,CHLOE LT,MAUREEN PM,et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J]. Nature,2010,461:798-802. [15] 周友乾,王小红,范熠,等. 抗丙型肝炎病毒治疗中的病毒学应答对持续应答的预测价值[J]. 中华肝脏病杂志,2009,17(12):944-946.